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Abstract
Background: The optimal timing of initiating renal replacement therapy (RRT) in critical illness complicated
by acute kidney injury (AKI) is not clearly established. Trials completed on this topic have been marked by
contradictory findings as well as quality and heterogeneity issues. Our goal was to perform a synthesis of the
evidence regarding the impact of “early” versus “late” RRT in critically ill patients with AKI, focusing on the
highest-quality research on this topic.
Methods: A literature search using the PubMed and Embase databases was completed to identify studies involving
critically ill adult patients with AKI who received hemodialysis according to “early” versus “late”/“standard” criteria.
The highest-quality studies were selected for meta-analysis. The primary outcome of interest was mortality at
1 month (composite of 28- and 30-day mortality). Secondary outcomes evaluated included intensive care unit (ICU)
and hospital length of stay (LOS).
Results: Thirty-six studies (seven randomized controlled trials, ten prospective cohorts, and nineteen retrospective
cohorts) were identified for detailed evaluation. Nine studies involving 1042 patients were considered to be of high
quality and were included for quantitative analysis. No survival advantage was found with “early” RRT among
high-quality studies with an OR of 0.665 (95 % CI 0.384–1.153, p = 0.146). Subgroup analysis by reason for ICU
admission (surgical/medical) or definition of “early” (time/biochemical) showed no evidence of survival advantage.
No significant differences were observed in ICU or hospital LOS among high-quality studies.
Conclusions: Our conclusion based on this evidence synthesis is that “early” initiation of RRT in critical illness
complicated by AKI does not improve patient survival or confer reductions in ICU or hospital LOS.
Keywords: Meta-analysis, Intensive care units (ICUs), Acute kidney injury (AKI), Renal replacement therapy (RRT), Early, Late
Background
Acute kidney injury (AKI) is a medical complication
associated with significant morbidity and mortality in
critically ill patients [1–3]. AKI is common in critical
illness, and severe AKI is associated with up to 60 %
hospital mortality [4]. Renal replacement therapy (RRT)
within the intensive care unit (ICU) is conducted as
either intermittent hemodialysis or continuous renal
replacement therapy (CRRT). Traditional indications for
RRT require the development of overt clinical manifesta-
tions of renal insufficiency, such as acidosis, electrolyte
disturbances (most notably hyperkalemia), uremic com-
plications (encephalopathy or pericarditis), and volume
overload unresponsive to aggressive medical management.
In spite of research and increasing clinical experience with
dialysis, the optimal time to initiate RRT in the course of
critical illness complicated by AKI is unclear.
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The notion of “early” RRT is to initiate dialysis therapy
before nitrogenous and other metabolic products accu-
mulate to the degree where they become relatively resist-
ant to therapy [5, 6]. Despite the intuitive rationale for
“early” RRT, there is limited evidence to guide clinicians
on the optimal time to initiate RRT in critical illness.
Neither standard clinical parameters nor research into
novel clinical biomarkers has emerged to clearly define
an ideal time or clinical picture where the initiation of
RRT optimizes patient outcomes. Earlier initiation of
RRT must be balanced with potential patient harm asso-
ciated with RRTs. Protocolled use of hemofiltration for
96 h in patients with septic shock admitted to an ICU
regardless of their renal function suggests that “early”
RRT can be associated with negative patient outcomes
[7]. As a result, research into “early” RRT includes
multiple definitions of early that reflect a potpourri of
time factors, biochemical markers, and clinical parameters
in an attempt to balance the risks of initiating RRT
with the benefits expected from supporting renal function
during critical illness.
The authors of two earlier meta-analyses pooled
available data on this topic to suggest that “early” RRT
improves survival in critical illness. Seabra et al. [8] iden-
tified 23 studies (5 randomized controlled trials [RCTs]/
quasi-RCTs, 1 prospective study, and 17 retrospective
cohort studies) and concluded that “early” initiation of
RRT was associated with 28 % mortality risk reduction
(relative risk [RR] 0.72, 95 % CI 0.64–0.82, p < 0.001).
Karvellas et al. [9] identified 15 studies (2 RCTs, 4 pro-
spective studies, and 9 retrospective cohort studies) and
reached similar conclusions, reporting a significant im-
provement in 28-day mortality with “early” RRT (OR
0.45, 95 % CI 0.28–0.72, p < 0.001). However, the overall
findings were not congruent with the subgroup analysis
of randomized trials (RR 0.64, 95 % CI 0.4–1.05, p = 0.08),
where there was a signal that “early” RRT was not as-
sociated with a significant survival advantage. This has
diminished clinical confidence in the conclusions reached
by the earlier meta-analyses, and consequently “early”
RRT in critical illness remains a controversial therapeutic
intervention.
Since 2012, additional studies have been published that
do not support the conclusions of the previous meta-
analyses, and this has further diminished the confidence
in the previous conclusions that suggested a survival
benefit in critical illness associated with “early” RRT. We
conducted a systematic review and evidence synthesis to
investigate whether “early” versus “late” initiation of RRT
in critically ill patients with AKI improves patient sur-
vival and selected secondary outcomes for potential sig-
nals to suggest that “early” RRT may reduce patient
morbidity or enhance illness recovery. Our goal was to
identify the highest-quality studies on this topic and use a




This study was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [10] (see Additional file 1:
Figure S1 for PRISMA checklist). Our null hypothesis was
that “early” initiation of RRT does not improve patient
survival in critical care patients with AKI. This systematic
review was not registered, and a protocol does not exist.
The PubMed and Embase databases were searched to
identify published articles following four broad themes:
AKI, RRT, time of initiation, and critical illness (see
Additional file 2: Table S1 for search terms). SK is a
National Institutes of Health (NIH) physician and re-
quested the NIH librarian to provide oversight for the
search strategy. Our search was limited to English-
language-only, full-text primary research publications
(including abstracts with full text availability) report-
ing findings of clinical trials and observational studies
(cohort and case-control design) published between January
1985 and November 2015. Studies before 1985 were not
actively sought, owing to a low likelihood of relevance to
modern RRTs and critical care practices.
Study selection
References were screened and excluded if they were
small case reports or observational studies (fewer than
10 subjects), were not focused on critically ill adult
patients, did not report mortality data, involved basic
science data, or did not clearly distinguish between
“early” and “late” groups. This task was divided among
the authors. A second evaluation led by the senior au-
thor (RLCK) was conducted to evaluate study quality.
Studies were designated as being of “high quality” or
“low quality.” Studies were assigned a “low-quality” rat-
ing if there was no illness severity assessment between
cohorts or at the time of randomization (n = 8), signifi-
cant differences (p < 0.05) between cohort groups (n = 7)
at baseline, incomplete basic demographic data at baseline
(n = 6) to exclude baseline differences, or a Newcastle-
Ottawa Quality Assessment (NOQA) Scale [11] for cohort
studies rating less than 7 (n = 6). The senior author
(RLCK) was the arbiter in cases of disagreement. Only
high-quality studies were included in quantitative meta-
analysis of the primary and secondary outcomes.
Primary and secondary outcomes
The primary outcome of interest was mortality at 1 month
(pooling outcomes for mortality at 28 or 30 days, depend-
ing on what was reported by the primary authors). In
addition to mortality, we analyzed selected secondary
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Table 1 Trial Summary Table by Study Type (n=36)





























Multisystem 106 70 36 EHV: 68;
ELV: 70;
LLV: 67
EHV: SOFA 10.3 -
APACHE2=23.5,
ELV: SOFA 10.1 -
APACHE2=21.7;
LLV: SOFA 10.6 -
APACHE2=23.6
TIME: Early
< 12 h (200ml);
Early Low Vol

































Early 1/21 (4.8%) died,





























Mean time to RRT
start 1.7d±0.8 post op
HIGH 14 d mortality: Early 2/14
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unless metabolic
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present
HIGH Early 20/37 (54%) died,
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unresponsive to med mgmt
HIGH Mortality: Early 40/112
(36%) died, Late 40/112
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refractory to medical therapy,
Uremic symptoms Mean
time to RRT=32hrs
HIGH Mortality: Early 16/48
(33%) died,










Table 1 Trial Summary Table by Study Type (n=36) (Continued)
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TIME: Early RRT started for
azotemia (Urea>30mmol/L
or low urine output × 12h)
<2d (n=785), Delayed
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Spain 2 years NR Multisystem 148 44 104 All patients
mean = 60; NR
Early: APACHE2=26;
Late: APACHE2=24
BIOCHEM: RRT initiated for
RIFLE: RISK & INJURY;
(Mean RRT start 2.2d
post ICU admit)
RRT initiated for RIFLE:
FAILURE; (Mean RRT start











Belgium 2001-2005 Pre existing renal
disease (Cr<1.5mg/dl),
reduced kidney size on
ultrasound
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Lim, 2014 [27] Single Centre
Prospective Cohort
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Table 1 Trial Summary Table by Study Type (n=36) (Continued)
baseline w/urine <0.3cc/kg/h















Prior RRT for CKD







TIME: AKI diagnosis to
randomization < 17.6 hrs























Trauma 100 41 59 Early 40;
Late 48
Early ISS = 33.0;
Late ISS = 37.2
BIOCHEM: BUN < 60mg/dL
AND Oliguria, Vol overload,
Electrolytes, Uremia; Mean RRT
start post admission
day 10; p<0.0001
BUN > 60 mg/dL AND Oliguria,
Vol overload, Electrolytes,


















64 36 28 Early 69;
Late 68
NR BIOCHEM: Low
urine output = less than




≥30mmol/L, Cr Elahi, 2004 [29]
≥250mmol/L, K > 6.0mEq/L;















61 34 27 NR p=0.3 NR BIOCHEM: Low
urine output = less than
100ml within 8hrs
post op; Mean RRT
start 0.88 days
Cr≥5mg/dL, or K>5.5 mEq/L
w/med mgmt; Mar 92-Jun 96;











































Brazil 2002-2005 Patients who did
not have both AKI and
respiratory failure believed
secondary to leptospirosis





to RRT = 265 min










Malta 1995-2006 NR Post Cardiac
Surgery








Oliguria (output < 0.5ml/Kg/hr)
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US 2000-2004 Baseline eGF0R
<30ml/min, Age
<18 & prisoners





<100mg/dL + AKIN stage >2;
Mean ICU stay prior
to RRT =6.3days
BUN > 100mg/dL + AKIN stage













Taiwan Jan 2002 -
Oct 2009
Age< 18, ICU stay
<2days, RRT < 2days



























Multisystem 230 NR NR All patients
mean = 66 NR
NR TIME: Time from AKI to
RRT < 6 days
Time from AKI to RRT≥6d LOW
NOQA=5
OR for Late Mortality
(>6d) 11.66 (1.26-107.9)
P=0.0305, Favors Early
Ji, 2011 [36] Retrospective
cohort


















start of RRT 8.4hrs
Urine output <0.5ml/kg/h &
Time to RRT>12h post oliguria;























TIME: Time to development
of tradtional RRT
indications < 3d; Mean
time to start of RRT 1.4days
Traditional RRT indications
AND start of RRT > 3 days;
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189 52 137 All patients
mean = 72 NR
All patients
SAPS II Mean= 57
BIOCHEM: RIFLE ‘Risk’ RIFLE ‘Injury’ or ‘Failure’ LOW
NOQA=6
Early: OR 0.361
(95 % CI 0.17–0.78);
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Table 1 Trial Summary Table by Study Type (n=36) (Continued)
Sepsis -
AKIN 3
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Lithuania 2007-2011 NR Sepsis 85 42 43 All patients
mean = 72 NR
NR TIME: Time from
anuria to RRT < 12hrs

















































LEGEND: AKI Acute kidney injury, AKIN Acute Kidney Injury Network, APACHE Acute Physiology and Chronic Health Evaluation, Cr Creatinine, CRF Chronic renal failure, CRRT Chronic renal replacement therapy, eGFR
Estimated glomerular filtration rate, EHV Early High Volume, ELV Early Low Volume, ESRD End stage renal disease, ICU Intensive Care Unit, LLV Late Low Volume, NOQA Newcastle-Ottawa quality assessment, NR Not
reported, NSARF National Taiwan University Hospital-Surgical ICU- Acute Renal Failure database, RIFLE Risk, Injury, Failure, Loss and End-stage, RPGN Rapidly progressive glomerularnephritis, SAPS2 Squential Acute










outcomes, including ICU length of stay (LOS) and hos-
pital LOS. Secondary outcomes were not consistently re-
ported for all studies, and only studies with applicable
data were included in our pooled analysis. Weighted
means were calculated as a product of the number of pa-
tients and mean duration to reach a total and represented
as a total of patient-days per study. These values were
summed and divided by the total number of patients from
all included studies to reach weighted mean duration of
LOS for both hospital and ICU LOS metrics. A similar
process was used to derive the mean weighted illness
severity scores. Other potentially relevant secondary out-
comes, including mechanical ventilation requirements,
vasopressor requirements, and renal recovery rates, were
considered, but these variables were inconsistently repor-
ted and commonalities could not be reached among the
heterogeneous parameters that were available.
Definition of “early” versus “late”
Early was defined on the basis of criteria used by the
original authors in their respective studies. We accepted
a broad definition of early based on biochemical markers
according to RIFLE classifications (risk, injury, failure,
loss of function, and end-stage kidney disease), Acute
Kidney Injury Network (AKIN) stages, or time-based
cutoffs (e.g., within a defined time from ICU admission
or development of a biochemical “start time”). Accepting
a broad definition of early was intended to optimize the
potential for identifying an effect associated with “early”
RRT. A limitation of this approach is that “early” accord-
ing to one study investigator might be considered “late” by
another study investigator. “Late” RRT criteria involved
either usual practice or expectant care (i.e., no RRT initi-
ated). “Usual practice” generally involved implementing
RRT following the development of classic RRT indications
unresponsive to medical management.
Statistical analysis
The quality of cohort trials was assessed using the
NOQA Scale (range from 0 to 9, with 9 indicating the
highest quality) [11]. The NOQA Scale for cohort studies
assesses the domains of population selection, comparabil-
ity of cohorts, and outcome assessment. A meta-analysis
was conducted using the high-quality studies to calculate
the pooled OR for mortality at 1 month. A random effects
model was used because of the significant heterogeneity
between studies on this topic. A random effects model is
indicated when study populations differ in ways that could
impact the results. Heterogeneity was assessed on the
basis of the Q value and I2 and τ2 statistics. A p value less
than 0.05 was considered statistically significant. All ana-
lyses were performed using Comprehensive Meta-Analysis
version 3.3.070 software (www.meta-analysis.com; Biostat,
Englewood, NJ, USA).
Results
The systematic literature search yielded 2405 references
that were subsequently refined to 36 studies eligible for
inclusion in this meta-analysis (see Additional file 3:
Figure S2 for article selection breakdown). These ref-
erences included 7 RCTs [7, 12–17], 10 prospective
cohort studies [18–27], and 19 retrospective cohort
studies [28–46]. Only nine studies met our criteria for
high quality [7, 12, 14–17, 21, 35, 40]. A summary of the
fundamental characteristics of all evaluated studies is pro-
vided in Table 1.
Primary outcome
The observed pooled crude mortality rates varied signifi-
cantly between the high- and low-quality studies. Among
the high-quality studies, the pooled “early” RRT study
group mortality rate was 34.6 % (192 of 555) compared
with 40.2 % (196 of 487) in the pooled “late” RRT group.
The low-quality studies demonstrated a pooled “early”
RRT group mortality rate of 51.3 % (1871 of 3645) com-
pared with 54.3 % (1486 of 2737) in the “late” RRT
groups. The most frequently reported measurement of
illness severity in the studies we analyzed was the Se-
quential Organ Failure Assessment (SOFA) score. The
SOFA score has been correlated with critical care patient
outcomes [47, 48], but it is not as robust as other scor-
ing systems validated in predicting survival (e.g., Acute
Physiology and Chronic Health Evaluation II [APACHE2]
or Simplified Acute Physiology Score II [SAPS2]) [49].
The mean weighted SOFA scores in the high-quality stud-
ies were 10.2 and 10.4 in the “early” and “late” groups,
respectively. SOFA scores were reported for 78 % of pa-
tients in the high-quality studies. Among the high-quality
studies, the SOFA score appeared to correspond with an
APACHE2 score of approximately 20 or a SAPS2 score of
approximately 53 when these additional illness severity
metrics were reported by the principal investigators. Un-
fortunately, more detailed quantitative evaluation of illness
severity using APACHE2 or SAPS2 scores was not pos-
sible, owing to heterogeneous reporting methods between
investigators and a lack of sufficient data. SOFA scores
were reported for 65 % of the patients in the studies
assigned low-quality ratings. The mean weighted SOFA
scores in the “early” and “late” groups among the low-
quality studies were comparable to those for the high-
quality studies at 10.0 and 9.2, respectively. No further
comments can be made regarding illness severity scores
among the low-quality studies, owing to lack of homoge-
neous and sufficient data. Illness severity scores for all
studies are summarized in Table 1.
Pooled analysis of the high-quality studies (n = 9) indi-
cates no mortality benefit with “early” versus “late” RRT,
with an OR of 0.665 (95 % CI 0.384–1.153, p = 0.146)
(Fig. 1). The bulk of the data in support of “early” RRT
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rests in the pooled low-quality studies (n = 27), with an
OR of 0.471 (95 % CI 0.343–0.649, p < 0.001) (Fig. 2).
Similarly to authors of previous meta-analyses, we found
very high heterogeneity among studies on this topic.
Heterogeneity was highest among the low-quality stud-
ies, reflected by a Q value of 163.8, I2 value of 84 %, and
τ2 = 0.495 (p < 0.001). Among the high-quality studies,
there continued to be statistically significant heterogen-
eity, with a Q value of 29.1, I2 value of 72.5 %, and τ2 =
0.481 (p < 0.001). Subgroup analysis of the high-quality
studies according to ICU admission type and surgical
[14, 16, 21] versus mixed medical admissions [7, 12,
15, 17, 35, 40] demonstrated no significant subgroup
mortality benefits associated with “early” RRT (see
Additional file 4: Figure S3a and b for forest plots by
ICU admission type). Subgroup analysis among the
high-quality studies was also conducted using the defin-
ition of early according to time criteria (hours or days)
versus biochemical parameters (i.e., rising creatinine,
uremia, oliguria) (see Additional file 5: Figure S4a and b
for forest plots by biochemical or time definition of early).
There were no significant effects observed in pooled mor-
tality trends in studies that defined early by time criteria
rather than on the basis of biochemical parameters.
Secondary outcomes
The secondary outcomes analyzed included ICU LOS
and hospital LOS. Five of the nine high-quality studies
reported ICU LOS data [12, 16, 17, 35, 40]. The mean
weighted ICU LOS in the “early” group was 9.4 days
(n = 351), compared with 10.8 days (n = 281) in the “late”
group. None of the studies reported a significant finding
with respect to ICU LOS and “early” RRT. Pooled analysis
for ICU LOS also demonstrated no significant change in
ICU LOS associated with “early” RRT, with a standard dif-
ference in the means of −0.035 (95 % CI −0.196 to 0.127,
p = 0.674) using a fixed effects model (Q = 0.598, p =
0.963) (Fig. 3). Hospital LOS was reported in five of nine
high-quality studies [12, 16, 17, 21, 40]. The mean
weighted hospital LOS in the “early” group was 19.3 days
(n = 317), compared with 17.1 days (n = 266) in the “late”
group. The pooled hospital LOS data do not reveal any
significant difference in hospital LOS using a fixed effects
Fig. 1 Mortality forest plot of pooled analysis of high-quality
studies (n = 9)
Fig. 2 Mortality forest plot pooled analysis of low-quality studies (n = 27)
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model with a standard difference in the means of 0.040
(95 % CI −0.125 to 0.204, p = 0.638) (Fig. 4).
Discussion
Despite several studies having been conducted on this
topic over the last 30 years, a clear answer regarding the
optimal timing of RRT in critical illness remains elusive.
Our analysis does not confirm the conclusions of previous
meta-analyses on this topic. Four studies [12, 14, 21, 35]
in the high-quality group were previously included in the
meta-analysis by Karvellas et al. [9], and only one
study [12] was included in the meta-analysis by Seabra et
al. [8]. The addition of four recently published studies
[15–17, 40] and one high-quality study that was not previ-
ously included in meta-analysis [7] accounts for our re-
sults that differ from those of earlier authors. Our
conclusions build on the concerns raised by both earlier
meta-analyses that the results of cohort trials in favor of
“early” RRT were not reproduced in methodologically
more rigorous study designs (i.e., RCTs). In our further
analysis we did not identify critical illness patient sub-
groups for whom “early” RRT might be more beneficial.
Similarly, how one defines early (according to time or on
the basis of biochemical characteristics) does not identify
a survival advantage associated with “early” RRT com-
pared with usual care. The optimal timing for initiation of
RRT is not clarified on the basis of research evaluated
to date.
The strength of our present analysis rests on our
extensive literature search and strict classification ac-
cording to study quality to limit risk of type I hypothesis
testing error. Prior meta-analyses relied heavily on retro-
spective cohort study data that possessed incomplete
preintervention data or preexisting significant differences
in groups which predisposed the investigators to identify a
survival difference attributed to “early” RRT that may have
been accounted for by the preintervention population dif-
ferences. We identified differences in the crude mortality
rates between the high- and low-quality studies that are
incompletely explained. The crude mortality rate differ-
ences may be explained by factors that are not adequately
controlled for between the groups before the intervention
of “early” versus “late” RRT (e.g., unreported regional insti-
tutional differences, variation in intensive care resources,
institutional setting variability [academic versus com-
munity], or natural history variability of the diseases
precipitating critical illness). In cohort trials, a differ-
ence in preintervention study groups indicates a
Fig. 3 Forest plot of pooled analysis of standard difference of the means for intensive care unit length of stay (n = 5)
Fig. 4 Forest plot of pooled analysis of standard difference of the means for hospital length of stay (n = 5)
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critical methodological flaw that precludes deriving
conclusions from their results. This is referred to as a
type I error in hypothesis testing and may falsely attribute
differences in outcomes to the study variable rather than
the differences between cohorts that existed before ana-
lysis. Among high-quality studies, there was no survival
advantage to “early” RRT with an OR of 0.665 (p = 0.146).
Any inclusion of the low-quality study data would signifi-
cantly pull the conclusion in favor of “early” RRT, which
would represent fulfillment of a type I statistical hypoth-
esis error. The strength of our work is that we vigorously
guarded against this possibility.
Subgroup analysis of the high-quality studies did not
reveal a survival benefit associated with either a surgical
or medical critical care patient population. This conclu-
sion remained the same regardless of whether early was
defined by time or on the basis of biochemical parame-
ters. Our secondary outcome analysis was limited by in-
consistent and incomplete data reported across studies.
Limited pooled analysis of the available data suggested
that there was no significant effect on either ICU or hos-
pital LOS associated with “early” RRT. Incomplete data
does not permit us to evaluate additional secondary out-
comes of interest (such as requirement for mechanical
ventilation or rates of renal recovery) that might also be
clinically relevant considerations factored into the deci-
sion to initiate RRT in critical illness.
By limiting our analysis to studies meeting high-quality
criteria, we dismissed a large volume of research on this
topic. A critique of our work is that we discarded studies
for methodological shortcomings that others may feel
should have been included. Most studies (n = 21) in the
low-quality group were excluded for incomplete cohort
data or significant preintervention differences between
cohort groups. The decision to exclude these trials is less
controversial than our decision to exclude cohort trials for
an NOQA Scale rating less than 7 (n = 6). This is poten-
tially controversial because the NOQA Scale has received
criticism regarding its validity and applicability in meta-
analysis cohort trial quality assessment [50]. The NOQA
Scale has received positive endorsement from some au-
thors [11], but detailed psychometric properties have not
been published in peer-reviewed journals to date. Further-
more, our selection of an NOQA Scale rating less than 7
to identify low quality is arbitrary. Our rationale for select-
ing this cutoff was that it necessitates that at least one of
the three NOQA Scale domains be seriously compro-
mised, and we felt that this represented a significant bias
predisposing the study results to committing a type I error
pattern. Seabra et al. [8] attempted to assign a quality
score to trials (0 = lowest quality to 5 = best quality) to
evaluate this domain, but their methodology for score
assignment was obscure and was not able to be replicated
or directly compared with our methods. In qualitative
comparison, the study assigned their top score [12] was
included in our quantitative analysis; however, their sec-
ond highest quality study [13] was excluded due to lack of
reported illness severity scores between groups. Including
studies with methodological errors does not advance sci-
entific understanding of this topic and has contributed to
the discordant findings on it.
Early studies on this topic were small and may have
overestimated an effect size associated with “early” RRT
based on the small size of the study populations. An ex-
ample of this problem is the Sugahara et al. study [14],
where 14-day mortality within the “early” group was
14 % (2 of 14), compared with 86 % (12 of 14) in the
“late” group (p < 0.01). While this study was included in
our quantitative analysis, the magnitude of the mortality
benefit reported in this trial associated with “early” RRT
has not been reproduced by subsequent investigators,
for reasons that are not clear. In our review of the ongoing
trials on this topic registered with the NIH (www.clinical
Trials.gov), we identified three trials [51–53] that may add
to knowledge in this area. The methodology of all three
active RCTs is roughly similar, with patients randomized
from a point in time triggered by the development of bio-
chemical renal injury reflected by a RIFLE grade of “fail-
ure” (at least one of rise in creatinine by minimum of
300 %, oliguria less than 0.3 ml/kg/h for 12 h, or anuria
lasting more than 12 h). From this biochemical entry
point, patients will be randomized to immediate initiation
of RRT (goal time to RRT less than 12 h) or standard care
(RRT initiated after failure of medical management to
temporize metabolic derangements or volume overload).
These study designs are similar to the design used by
Wald et al. [17], included in our analysis, that was able to
separate an “early” group to mean time to RRT of 9.2 h
and a “late” RRT group with a mean time to RRT of 32 h
after biochemical inclusion criteria were met. Wald et al.
[17] did not identify a significant difference in mortality
rates between their two groups (p = 0.74). These studies in
process will add to the quantity of patients evaluated in
this manner and will build on the availability of high-
quality data on this topic. By clearly defining routine bio-
chemical criteria associated with acute renal injury, they
provide a practical method of renal injury assessment that
can be determined by intensivists and nephrologists con-
sidering RRT.
Conclusions
The results of our meta-analysis contradict the findings
reported by previous authors [8, 9], and we conclude
that “early” initiation of RRT in critically ill patients with
AKI does not improve survival. This conclusion is de-
rived from the pooled high-quality trial data and excludes
data from cohort trials where there were methodological
shortcomings that predisposed them to find an effect
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misattributed to the intervention. Pooled analysis of
secondary outcomes did not demonstrate a statistical
reduction in ICU or hospital LOS. Additional well-designed
RCTs will provide greater confidence in these conclusions
as optimal patient care practices progress in critical care.
Clinical triggers for the initiation of RRT to optimize pa-
tient outcomes have not been clearly identified by current
research. Meanwhile, intensivists and nephrologists are
encouraged to refrain from lowering their clinical thresh-
olds for implementing RRT in critical care patients with
acute renal injury.
Key messages
 High-quality trial data do not demonstrate improved
survival using an “early” RRT approach in critical
illness complicated by AKI.
 Lower-quality trial data demonstrate significantly
higher mortality rates and form the basis for the
bulk of support for “early” AKI.
 The optimal time to initiate RRT in critical illness
remains undefined.
 A conservative approach to initiating RRT in critical
illness is supported.
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